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Summary: Sensitive enzyme immunoassays for the determination of total leukocyte neutral proteinase inhibitor
and polymorphonüclear elastase-leukocyte neutral proteinase inhibitor complexes are described. The usable
ranges of the standard curves were from 80 ng/1 to 10 g/I. The relative intra-assay coefficients of variation
of the tests were between 2 and 4%, and the inter-assay coefficients of variation between 4 and 10%. In vitro
and in Vivo studies were performed with septic pigs and isolated leukocytes. The results show that leukocyte
neutral proteinase inhibitor can be used in pigs as a parameter for the development of a septicaemia.
Introduction The main inhibitory activity directed against neutral
During severe inflammatory processes various blood proteinases is due to leukocyte neutral proteinase
and tissue cells including polymorphonüclear granu- inhibitor, a potent inhibitor found in the cytosol of
locytes may release cellular constituents such as ly- leukocytes (7). Besides -proteinase inhibitor, which
sosomal proteinases and inhibitors from the cytosol is present in plasma2) and interstitial fluid, leukocyte
extracellularly into the circulation (1—4). Such en- neutral proteinase inhibitor represents an additional
zymes as well as oxidizing agents are released during potent intracellular neutral proteinase inhibitory ca-
phagocytosis and enhance the inflammatory response parity.
by degrading connective tissue structures, membrane ™_ - .
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 temase inhibitor is of special interest and as yet not
oxidation (2,4). , ' '
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 ' clearly unterstood. Leukocyte neutral proteinase in-
Porcine leukocytes have been shown to contain hibitor may, on the one hand, act as part of an
proteolytie1) as well as inhibitory activities (5 — 7). intracellular defence system to regulate undesired pro-
J) this journal, Vol. 23, 637-643 (1985) 2) this journal, Vol. 23, 821-828 (1985)
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teolytic activities inside the cells by complex formation
with proteinases. On the other hand, it could assist
the overall inhibitory potential of the organism in
blood, e. g. in inflammatory processes (8), in which
leukocytes release large amounts of proteinases by
degranulation or during disintegration (9); leukocyte
neutral proteinase inhibitor may also serve both of
these purposes.
Thus leukocyte neutral proteinase inhibitor is an ad-
ditional protection against proteinases in the cytosol.
This is in contrast to human leukocytes, in which only
small amounts of inhibitors have been described (10).
In this communication we describe the evaluation of
enzyme immunoassays which can be used to measure
plasma concentrations of leukocyte neutral proteinase
inhibitor and its complex with polymorphonuclear
leukocyte elastase3), and their application in experi-
mental septicaemia in pigs. Furthermore, we report
studies dealing with the release of leukocyte neutral
proteinase inhibitor from polymorphonuclear granu-
locytes by stimulation with different agents such as
endotoxin, zymosan, etc.
Material and Methods
Porcine leukocyte elastase from porcine blood was isolated as
described (11). Leukocyte neutral proteinase inhibitor was puri-
fied and characterized as reported recently (7).
Antibodies directed against porcine leukocyte elastase and leu-
kocyte neutral proteinase inhibitor were raised in rabbits using
a known protocol (12). Anti-leukocyte neutral proteinase in-
hibitor immunoglobulin G was isolated according to Steinbuch
& Audran (13). Anti-leukocyte neutral proteinase inhibitor IgG
peroxidase conjugate was synthesized as described (14).
Enzyme immunoassay4) conditions
In test samples, e. g. in porcine blood, leukocyte neutral pro-
teinase inhibitor may occur in a free, i. e. active form, or as a
polymorphonuclear leukocyte elastase-inhibitor complex, or as
a neutral proteinase other than elastase-inhibitor complex. For
the determination of leukocyte neutral proteinase inhibitor and
its complex with polymorphonuclear leukocyte elastase two
enzyme immunoassays were used, ELISA type A and ELISA
type B. With ELISA type A the total amount of leukocyte
neutral proteinase inhibitor (free inhibitor,' complex with po-
lymorphonuclear leukocyte elastase and with another neutral
proteinase, e. g. chymase) can be determined. With ELISA type
B, only free inhibitor and its complex with proteinase other
than elastase can be measured. The difference between ELISA
type A and ELISA type B is a preincubation step in ELISA
type B, in which elastase-inhibitor complex and traces of free
3) Enzymes
Porcine polymorphonuclear leukocyte elastase (EC 3.4.21.37,
formerly EC 3.4.21.11)
4) Abbreviations
ELISA enzyme-linked immunosorbent assay
ABTS: 2,2'-azinobis (3-ethylbenzthia2oline) sulphonic acid
IgG: immunoglobulin G
elastase are bound to anti-polymprphonuclear leukocyte elas-
tase antibodies fixed to a microtitre plate surface. In all assays
authentic leukocyte neutral proteinase inhibitor is used as
standard. Determination of the protein concentration of leu-
kocyte neutral proteinase inhibitor solutions was performed by
amino acid analysis. Uncomplexed leukocyte neutral proteinase
inhibitor can be measured as described in 1. c. (7).
Buffer A: 15 mmol/1 Na2CO3> 35 mmol/1 NaHCO3, 3 mmol/1
NaN3, pH 9.6
Buffer B: 1.5 mmol/1 KH2PO4, 65 mmol/1 Na2HPO4, 137
mmol/1 NaCl, 0.5 g/1 Tween 20, pH 7.4 (dilute 1:10
before use)
Buffer C: 0.15 mmol/1 KH2PO4, 6.5 mmol/1 Na2HPO4, 13.7
mmol/1 NaCl, 0.05 g/1 Tween 20, 20 g/l bovine serum
albumin, pH 7.4
Buffer D: 0.1 mol/1 citric acid, 0.1 iriol/l Na2HPO4, pH 4.5
ELISA type A
(Determination of free inhibitor and its complexes with elastase
and neutral proteinase other than elastase; fig. 1 a)
Microtitre plates were coated with anti-leukocyte neutral pro-
teinase inhibitor IgG (2 mg/1 buffer A; 0.2 ml per well) at 4 °C
overnight. The plates were then washed (5 times) with buffer
B. Standard samples of leukocyte neutral proteinase inhibitor
and test samples were diluted with buffer C. Of these samples
0.2 ml were added to the wells and the plates were incubated
at 37 °C for 3 h. After incubation, the plates were washed (5
times) with buffer B; 0.2 ml of anti-leukocyte neutral proteinase
inhibitor IgG peroxidase conjugate solution was then added to
each well and incubated for 3 h at 37 °C. After washing, per-
oxidase activity was measured as described in ELISA type B.
Leukocyte neutral proteinase inhibitor was used as the stand-
ard.
ELISA type B
(Determination of free inhibitor and its complex with neutral
proteinase other than elastase; fig. 1 b)
Preabsorption of polymorphonuclear leukocyte elastase and its
complex with elastase: microtitre plate A was coated with änti-
polymorphonuclear leukocyte elastase IgG (2.5 mg/l in buffer
A; 0.2 ml per well) overnight at 4 °C. After incubation microtitre
plate A was washed with buffer B (5 times). Decreasing dilutions
of each test sample (e. g. porcine blood) were prepared in buffer
C and 0.2 ml of these samples were added to the wells. Plate
A was incubated at 4 °C for 24 h to bind polymorphonuclear
elastase and its complex with neutral proteinase inhibitor. A
second microtitre plate B was coated in parallel with anti-
leukocyte neutral proteinase inhibitor IgG (2.0 mg/1 in buffer
A; 0.2 ml per well) overnight at 4 °C.
Determination of leukocyte neutral proteinase inhibitor and its
complex with neutral proteinase other than elastase: after in-
cubation, microtitre plate B was washed (5 times) with buffer
B and a standard solutions of leukocyte neutral proteinase
inhibitor in decreasing dilutions in buffer C was added to the
microtitre plate B wells. In addition, preincubated test samples
(see above under preincubation step) in microtitre plate A were
gently shaken for 5 min and then transferred to the correspond-
ing wells of microtitre plate B. Titre plate B was incubated
either for 3 h at 37 °C or overnight at 4 °C. After washing plate
B (5 times with buffer B), 0.2 ml of anti-leukocyte neutral
proteinase inhibitor IgG peroxidase conjugate solution in buffer
Gwas added to each well and plate B was incubated again for
3 h at 37 °C. After washing, peroxidase activity was measured
by adding 0.2 ml substrate solution (0.5 ml ABTS® solution
(20 g/1 H2O), 9.5 ml buffer D and 0.2 ml H2O2 (300 g/l) to the
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Fig. l a ABTS
Dye
Fig. l b.
Fig. l a. Scheme of the enzyme immunoassay type A of leukocyte neutral proteinase inhibitor (free inhibitor and its complexes
with elastase and neutral proteinase other than elastase).
Fig. 1 b. Scheme of the enzyme immunoassays type B of free inhibitor and its complexes with elastase and neutral proteinase
other than elastase.
In enzyme immunoassay type B a preselection of polymorphonuclear leukocyte elastase and its complex with elastase
on microtitre plates coated with anti-elastase antibodies was performed.
IP, leukocyte neutral proteinase inhibitor; E, leukocyte elastase; P, neutral proteinase; ABTS = 2,2'-azinobis(3-
ethylbenzthiazoline) sulphonic acid; >—, anti-leukocyte neutral proteinase inhibitor antibodies; >—·, anti-leukocyte
neutral proteinase inhibitor peroxidase conjugate; £±3, anti-leukocyte elastase antibodies; IE polymorphonuclear
leukocyte elastase inhibitor other than leukocyte neutral proteinase inhibitor.
wells. Plate B was incubated for 30 min at 37 °C. The absorb-
ance was read photometrically at 405 nm with a Microelisa^-
reader MR 600 from Dynatech, Denkendorf, FRG. The back-
ground generally ranged from Α^5 == 0.02 to 0.08. Standard
curves for leukocyte neutral proteinase inhibitor were con-
structed by plotting the fraction of absorbance at 405 nm, A-
N/Ao-N (A: absorbance, A0: maximal absorbance obtained with
excess leukocyte neutral proteinase inhibitor, N: absorbance of
the blank) against the dose of leukocyte neutral proteinase
inhibitor in a semi-log mode.
itor complexes and lactate dehydrogenase. For control meas-
urements, physiological saline was used instead of a stimulant.
To stimulate leukocyte suspensions in physiological saline 6 ml
of whole blood were centrifuged for 10 min at 4000 g. The
leukocyte sediment was gently resuspended in saline, centri-
fuged again (in total 3 times) and suspended in 6 ml saline. The
leukocyte stimulation was performed as described for whole
blood.
Animals and cells
Septicaemia was induced in domestic pigs under pentobarbital
anesthesia by infusion of 3 χ ΙΌ ·° live bacteria over 2 h (E.
coli, ATCC strain 20399), Plasma samples were taken before
infusion and at 2 h intervals thereafter.
Stimulation of leukocytes in whole blood was performed as
follows: 6ml whole blood and 0.12 ml stimulating reagent
solution (6.96 mg zymosan, 0.06 mg endotoxin and 5 χ ΙΌ7
live E. coli) were incubated at 37 °C. Saniples of 0.5 ml were
taken at different time intervals and centrifuged at 12000g.
The supernatants were used for the determination of leukocyte
neutral proteinase inhibitor, leukocyte neutral proteinase inhib-
Results and Discussion
Enzyme immunoassays for the specific determination
of polymorphonuclear leukocyte elastase-leukocyte
neutral proteinase inhibitor complexes and free inhib-
itor alone were developed. After a large series of
experiments using numerous types of enzyme immu-
noassay conditions (combination of different antibod-
ies for coating, etc.), the final methodology permitted
an accurate determination of both elastase complexed
and total leukocyte neutral proteinase inhibitor (free
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inhibitor and its complexes with elastase and neutral
proteinase other than elastase) in test samples. The
assays were optimized with respect to
(i) enzyme immunoassay conditions (binding of an-
tigen/antibody to microtitre plates, antibody-antigen
binding, etc.) as previously described (15), and to
(ii) detection system conditions (concentration of sub-
strates, temperatures, etc.).
Using the given incubation conditions standard curves
were obtained as shown in figure 2. In both assays
(ELISA type A and B) leukocyte neutral proteinase
inhibitor was used as standard, because the elastase-
inhibitor complex was stable for no longer than three
weeks at — 30 °C. Comparative studies performed
with leukocyte neutral proteinase inhibitor and its
elastase complex as standards showed no differences
in standard curves. The lower limits of detection were
about 80 ng/1 in ELISA type A and 120 ng/1 in ELISA
type B. The intra-assay coefficients of variation
(n = 10) were between 2 and 4% (ELISA type A and
B); the inter-assay coefficients of variation of identical
samples (n = 50) were between 4 and 9% (ELISA
type A and B). The high specificity of both assays
was demonstrated by adding various serine protei-
nases and inhibitors to the tests. No cross-reactivity
was observed.
Elastase complexed and free inhibitor concentrations
were determined using the newly developed enzyme
immunoassays. Plasma levels of elastase complexed
inhibitor were calculated by subtraction of the meas-
ured concentrations of free inhibitor and its complex
with neutral proteinase other than elastase from the
sum of the concentration of free inhibitor and its
0.01 0.1 1 10 100
Leukocyte neutral proteinase inhibitor [μς/Ι]
Fig. 2. Dose response curves of total leukocyte neutral protein-
ase inhibitor (B; free inhibitor and its complexes with
elastase and neutral proteinase other than elastase) and
residual leukocyte neutral proteinase inhibitor (a; free
inhibitor and its complex with neutral proteinase other
than elastase).
complexes with elastase and neutral proteinase other
than elastase. The plasma concentration of neutral
proteinase inhibitor and its complexes with elastase
and neutral proteinases other than elastase in non-
septic pigs was found to be 150 .± 30 ng/1 blood, and
for elastase-inhibitor complex of 16 ± 11 μ^Ι. In
porcine leukocytes a neutral proteinase inhibitor con-
tent of 64 fg/polymorphonuclear granulocyte was
measured.
The sensitive and specific enzyme immunoassays de-
veloped for the detection of elastase complexed leu-
kocyte neutral proteinase inhibitor and total leuko-
cyte neutral proteinase inhibitor (free inhibitor and
its complexes with elastase and neutral proteinase
other than elastase) were used for model studies in
pigs. Leukocyte neutral proteinase inhibitor released
by desintegration of leukocytes may appear in plasma
of pigs either as free inhibitor or as elastase-leukocyte
neutral proteinase inhibitor complex, or complexed
with other neutral proteinases, such as mast cell chy-
mase.
During the development of septicaemia with live E.
coli, plasma concentrations of leukocyte neutral pro-
teinase inhibitor and its complex with elastase approx.
10 times higher than thq normal physiological levels
were observed in septic pigs (n = 8; fig. 3). Thus
leukocyte neutral proteinase inhibitor may serve as a
marker of the inflammatory response of the granu-
locytes in septic pigs.
In in vitro studies we stimulated both porcine leu-
kocytes in whole blood (fig, 4 a) and washed leuko-
cytes (fig. 4b) using zymosan, live E. coli and endo-
toxin. Disintegration of leukocytes was monitored by
determination of lactate dehydrogenase. As can be
seen from figure 4, only zymosan induced a noticeable
release of leukocyte neutral proteinase inhibitor after
about 30 min. The release of leukocyte neutral pro-
teinase inhibitor induced by E. coli and endotoxin is
mainly due to disintegration of the cells during in-
cubation. This is in contrast to data described for the
release of elastase after stimulation of human leuko-
cytes (16). Obviously, the inhibitor is liberated from
the cells only slowly, and a potent stimulus or even
disintegration of the cells may be necessary for the
release reaction.
The less ready release of the inhibitor compared with
that of polymorphonuclear leukocyte, elastase, may
be due to its localization in the cytosol of the leuko-
cytes. Leukocyte elastase is stored in lysosomal gran-
ules of the cell, whereas leukocyte neutral proteinase
inhibitor has been found only in the cytosol. Whether
the release reaction is of physiological significance
remains to be clarified by future studies.
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Fig. 3 a. Mean plasma concentrations of total leukocyte neutral
proteinase inhibitor (free inhibitor and its complexes
with elastase and neutral proteinase other than elas-
tase) in septic pigs (n = 8).
Fig. 3 b. Mean plasma concentrations of elastase-inhibitor
complex in septic pigs (n = 8).
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Fig. 4. In vitro stimulation of polymorphonuclear leukocytes
(a, leukocytes in whole blood; b, washed leukocytes).
Δ, zymosan (1 g/(l χ ΙΟ3 leukocytes); n, E. coli
(5 χ 107);o, endotoxin (10 g/1). For details see Material
and Methods.
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